Rybelsus
Indicated to manage type 2 diabetes and developed to support blood sugar control and alleviate weight-related health risks in patients.
- Categories
- Diabetes Management · Weight Management
- Active ingredient
- Semaglutide
- Supply
- Rx
- Route
- Oral use
- Form
- Tablet
- Strengths
- 3 · 7 · 14mg
Rybelsus details
- Condition
- Type 2 Diabetes Mellitus
- Alternative names
- Ozempic; Wegovy
- Therapeutic class
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
- Pharmacological class
- GLP-1 Receptor Agonist
- Known off-label uses
- obesity
- Precautions and warnings
- maintain adequate hydration; monitor blood sugar levels
- Minor side effects
- nausea; diarrhoea
- Moderate side effects
- vomiting; abdominal pain; constipation
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Novo Nordisk
- Onset Time
- weeks
- Duration
- long term
- Storage instructions
- Store in original card in a dry place.
- Drug interactions
- insulin; sulphonylureas
- Age restrictions
- 18 years and older.
- Pregnancy and breastfeeding
- Not recommended during pregnancy.
Contraindications
medullary thyroid carcinoma history; multiple endocrine neoplasia syndrome type 2
Serious side effects
pancreatitis, requires immediate medical attention; gallbladder disease, requires immediate medical attention
Patient summary
Indicated to manage type 2 diabetes and developed to support blood sugar control and alleviate weight-related health risks in patients.
Mechanism of action
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. It enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, which helps to lower blood glucose concentrations and promote satiety.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Rybelsus
Rybelsus is a medication containing semaglutide, which is indicated for the management of Type 2 diabetes mellitus. The same active ingredient is also sold as Ozempic and Wegovy. It is supplied as a tablet in strengths of 3, 7 and 14mg, and is produced by Novo Nordisk.
Rybelsus availability in Asia
Rybelsus is registered across 14 markets including Malaysia, the Philippines and Indonesia, with availability also in Taiwan, South Korea and Japan. Generic versions of semaglutide, much of it made in India, are also accessible and far more affordable than the original brand. This offers a practical solution for expats and those residing far from a well stocked facility, though this medication is best used under the care of a doctor.